Partnerships
Pluristyx partners with leading biotechnology and pharmaceutical companies, academic institutions and research organizations to support and accelerate the development and commercialization of revolutionary therapeutics.
Pluristyx's partnerships, collaborations and strategic alliances accelerate clinical timelines of genomically stable pluripotent stem cells and cell therapy solutions.
Teknova
Pluristyx has entered into a collaboration agreement with Teknova for the manufacture and commercialization of Pluristyx’s proprietary cryopreservation system, PluriFreezeTM, including wash and storage products, in the US and Canada. As a leading reagents manufacturer with nearly 30 years’ experience producing research- and GMP-grade products for the life sciences industry, Teknova will help expand access to this novel cryopreservation solution designed to simplify the scale-up process for companies working to bring allogeneic cell therapies to market.
Charles River
Pluristyx has entered into an agreement with Charles River Laboratories International, Inc. The collaboration provides Charles River with broad access to highly characterized and unique stem cell lines, including high-quality embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs) as research tools to support development of new therapeutics.
StemGenomics
In July 2023, Pluristyx and Stem Genomics announced the closing of an equity investment and strategic partnership in Stem Genomics. Through the partnership, the companies will offer a unified pathway to allow customers to evaluate the genomic stability of Pluristyx’s pluripotent stem cell (PSC) lines using Stem Genomics’ iCS-digital™ PSC assay.
Advanced Regenerative Manufacturing Institute (ARMI)
In July 2023, Pluristyx announced an agreement with the Advanced Regenerative Manufacturing Institute | BioFabUSA to manufacture and commercialize Pluristyx’s clinical-grade reprogrammed induced Pluripotent Stem Cells (iPSCs). Pluristyx, Inc. today announced an agreement with the Advanced Regenerative Manufacturing Institute | BioFabUSA to manufacture and commercialize Pluristyx’s clinical-grade reprogrammed induced Pluripotent Stem Cells (iPSCs).
California Institute for Regenerative Medicine
In June 2023, Pluristyx announced its’ acceptance as an Industry Resource Partner (IRP) with the California Institute for Regenerative Medicine (CIRM). This partnership provides CIRM awardees with improved access to Pluristyx / panCELLa’s highly-characterized and genetically-modified induced Pluripotent Stem Cells (iPSCs) containing industry-leading FailSafe™ and iACT Stealth Cell ™ technologies.
Stemmatters
In May 2023, Pluristyx and Stemmatters announced a collaboration focused on the advancement of next generation of iPSC-derived Mesenchymal Stem Cells (iMSCs), engineered iMSCs and biological products produced from conditionally immortalized iMSC lines that include exosomes and conditioned media. The collaboration will focus on the large-scale manufacturing of iMSC banks for both non-clinical and clinical research projects, offering an end-to-end comprehensive range of services to clients developing iPSC-based technologies.
Resilience
Pluristyx, Inc., with expertise in gene-edited induced pluripotent stem cells (iPSCs) and National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines today, today announced a collaboration agreement to streamline the transition of promising iPSC-derived therapies from the benchtop to the bedside.